Please assess the completion status of the following clinical trial:

Trial Title: Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent provided for the subject by a parent or legal guardian~* Children age 6-35 months~Exclusion Criteria:~* Allergies to eggs, thimerosal, gentamicin sulphate or latex~* Life-threatening reaction to previous Flu vaccine~* Bleeding disorder~* Pregnancy~* Receipt of blood or blood products in past 3 months~* Chronic illness that could interfere with trial participation~* Compromised immune system~* Previous lab-confirmed H1N12009 infection~* Receipt of H1N12009 vaccine~* Receipt of Seasonal Influenza vaccine since March 2009

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Adjuvanted Arepanrix 2 doses (Type: ACTIVE_COMPARATOR): Two doses of adjuvanted H1N1 Arepanrix vaccine given 3 weeks apart

Based on this trial design, predict the completion outcome and termination type (if applicable).